Core Viewpoint - The company reported a revenue of 182 million yuan in the first half of 2025, facing challenges due to intensified industry competition and price fluctuations, but is focusing on core technology and new product development for long-term stability [1] Business Performance - The pharmaceutical intermediate business maintained stable revenue year-on-year, with a gross margin increase of 7.9 percentage points, acting as a stabilizer for the company's performance [1] - The raw material drug business experienced a short-term revenue adjustment due to market conditions, yet its gross margin improved by 9.82 percentage points, highlighting enhanced product value and market competitiveness [1] - The overseas market saw a gross margin increase of 12.78 percentage points, while the domestic market's gross margin rose by 4.52 percentage points, indicating growing recognition and bargaining power in global markets [1] R&D Investment - The company invested 20.9975 million yuan in R&D in the first half of 2025, a year-on-year increase of 29.87%, focusing on chemical synthesis and biological synthesis technologies [2] - The company has established a comprehensive product R&D system with multiple technology platforms, maintaining a competitive edge with unique and innovative production processes [2] - The company collaborates with key domestic universities and research institutions to enhance product development and has received significant scientific awards [2] Project Development - Two major investment projects reached operational status by June 30, 2025, expanding the company's capacity in nucleoside products and enhancing its product line [3] - The nucleoside raw material and intermediate project aims to improve supply capabilities in antiviral and antitumor products, while the nutritional enhancer project aligns with the health industry trends [3] Strategic Development - The company has outlined a clear strategy to accelerate the commercialization of R&D results, optimize personnel structure, and enhance operational efficiency [4] - The focus will be on increasing the added value of raw material drugs through technology upgrades and expanding the health product market [4] - The company plans to implement a dual-driven development strategy, concentrating on core areas in pharmaceuticals and deepening collaborations in the health industry to achieve breakthroughs in functional food [4]
拓新药业：筑牢长期技术壁垒 上半年研发投入同比增长29.87%